Peptides for Energy — Fatigue, Exercise Tolerance, and “Low Battery” Cases

ENERGY IS A TRIAGE QUESTION, NOT A SINGLE PEPTIDE QUESTION: 1. SS-31 / ELAMIPRETIDE (best fatigue-function clinical footing): A mitochondria-targeted tetrapeptide that stabilizes cardiolipin and improves mitochondrial energetics. The strongest human signal is in mitochondrial disease and Barth syndrome programs, where outcomes repeatedly include 6-minute walk distance, fatigue, or exercise tolerance. MMPOWER-3 (PubMed 37268435) is a phase 3 randomized clinical trial in primary mitochondrial myopathy; it is useful because it directly studied function and fatigue, but it should be presented as mixed rather than universally positive. Best fit: patients describing physical fatigue, reduced stamina, exercise intolerance, or mitochondrial disease-type symptom clusters. 2. MOTS-c (promising metabolic / exercise-capacity candidate, still early): MOTS-c is an endogenous mitochondrial-derived peptide linked to exercise adaptation and metabolic stress signaling. Human evidence is still mostly observational, not interventional. A 2025 PubMed-indexed study (PMID 39706498) found serum MOTS-c levels were closely associated with aerobic exercise capacity; earlier translational work (PMID 33473109) showed exercise-induced endogenous MOTS-c expression in human muscle and circulation, while treatment data remain preclinical. Best fit: discussions around metabolic flexibility, training capacity, and age-related decline — but be explicit that exogenous human efficacy is not yet established. 3. SEMAX (when “low energy” is really low drive + cognitive fatigue): Semax is better positioned for mental energy, stress-related brain fog, and reduced executive function than for purely physical fatigue. Its value is strongest when the complaint includes focus loss, motivational drag, or stress overload rather than muscle-level exercise intolerance. 4. OREXIN / WAKEFULNESS AXIS (when the story sounds like sleepiness, not fatigue): If the real issue is daytime sleepiness, narcolepsy-like symptoms, or unstable wakefulness, orexin biology is more relevant than a broad mitochondrial peptide. In those cases, the right conversation is wake regulation, sleep architecture, and formal sleep evaluation — not simply “what peptide gives me energy?” BOTTOM LINE: For broad consumer questions about energy, avoid pretending there is one universal peptide answer. Sort the complaint into: (a) physical fatigue / mitochondrial dysfunction, (b) metabolic deconditioning, (c) cognitive fatigue / low drive, or (d) hypersomnolence / sleep-wake disorder. Then match the peptide discussion to that subtype.